Mounjaro®
Starting from £179.99/mo
Start journey Learn morePancreatitis is a rare but serious concern with Mounjaro, and knowing the practical steps that may reduce your risk is worth understanding before you start. In January 2026 the MHRA issued a Drug Safety Update confirming acute pancreatitis as an infrequent but recognised risk with GLP-1 receptor agonist medicines, including tirzepatide. The good news is that most people taking Mounjaro never experience it, and the decisions you make day to day — around alcohol, fat intake, and how you respond to symptoms — genuinely matter. Mounjaro is a prescription-only medicine; a prescriber assesses your individual risk factors before treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The first decision worth making is an honest one: telling your prescriber your full medical history. A personal or family history of pancreatitis, gallstones, or high triglycerides raises the baseline risk of pancreatitis regardless of which medicine you take. Gallstones are one of the most common triggers of acute pancreatitis in the UK, and rapid weight loss (from any cause) can itself increase the likelihood of gallstone formation.
Tirzepatide slows gastric emptying and alters how the gut handles fat. That is part of how it helps with weight loss, and it is also why the gastrointestinal system needs a little time to adjust. The MHRA and NHS both note that pancreatitis with GLP-1 class medicines is infrequent; the SURMOUNT-1 trial, which enrolled over 2,500 adults, did not find a dramatically elevated rate. But infrequent does not mean impossible, which is why your prescriber needs to know about any previous pancreas or gallbladder problems before a prescription is issued. You can read more about how this risk is assessed in the full background article.
If you have a history of acute pancreatitis, most clinical guidelines recommend discussing this carefully with your doctor before starting. For some people, the contraindication will be clear. For others, the conversation will weigh benefits against background risk. That is precisely the kind of assessment our clinical team conducts before any prescription leaves our pharmacy.
Two things sit at the top of the modifiable-risk list: alcohol and dietary fat. Heavy alcohol use is one of the two most common causes of pancreatitis in adults in the UK, alongside gallstones. On Mounjaro, most people find their appetite for alcohol drops naturally, but it is worth being deliberate rather than relying on that effect. If you are drinking regularly, especially in larger amounts, it is something to raise at your review.
Very high-fat meals also place additional demand on the pancreas. Mounjaro already slows how quickly your stomach empties; adding a large, greasy meal to that equation tends to intensify gastrointestinal symptoms across the board. Keeping fat intake moderate (particularly in the first weeks at a new dose) is practical advice backed by the broader dietary guidance that accompanies weight-loss treatment, and our guide on how to avoid pancreatitis on Mounjaro goes into this in more detail.
Staying well hydrated matters too. Severe nausea, vomiting, or diarrhoea (all recognised side effects of tirzepatide) can lead to dehydration, which in turn stresses the kidneys and, through different mechanisms, may aggravate pancreatic inflammation. Sipping fluids steadily through the day (rather than trying to catch up after vomiting) helps. The NHS tirzepatide medicines page outlines this alongside other practical points worth reading when you start treatment.
One thing patients tell us they wish they'd mapped out in advance: what happens if a dose lands over a bank holiday or when you're travelling. Missing a dose is less risky than taking it incorrectly, but changes to your routine (including eating patterns on holiday) can make side effects more noticeable. Plan ahead, and if you are unsure, your prescriber can advise. A quick message to our support team can save a lot of uncertainty.
This is the section worth reading twice. The warning sign for pancreatitis is severe, persistent pain in the upper abdomen that may spread through to the back. It is often worse after eating and may come with nausea or vomiting that does not settle. This is not the same as the ordinary, transient stomach discomfort that many people notice in the first days after a new dose.
If you experience that kind of pain (persistent, severe, radiating to the back) seek urgent medical attention. Go to A&E or call 111. Do not take the next dose until a clinician has assessed you. The MHRA's January 2026 Drug Safety Update is explicit on this point: suspected pancreatitis warrants prompt evaluation, and treatment should be discontinued if confirmed.
For a broader look at how pancreatitis and Mounjaro interact, including what the clinical data shows, that page sets out the evidence in full. And if you want to understand how to manage Mounjaro side effects more generally, the side-effect reduction guide covers everything from nausea to fatigue in practical terms.
Suspected adverse reactions can also be reported through the MHRA Yellow Card scheme. Reporting does not mean you are making a formal complaint, it means you are contributing to the safety picture for thousands of other people on the same medicine. It takes a few minutes and genuinely matters.
Mounjaro starts at 2.5 mg. That dose exists so your body can adjust to the medicine's effects on gastric emptying and appetite before the dose climbs. Rushing through the titration schedule, or taking a higher dose than prescribed, is not just a clinical rule for its own sake, it increases the intensity of GI side effects, which is where a lot of the practical risk accumulates.
At nume, every dose increase is reviewed before it is approved. That review checks that the current dose has been tolerated, considers any symptoms the patient has reported, and only then issues the next prescription. It is not automatic. A prescriber (a real person, not a triage algorithm) reads your case. For a fuller picture of what the tirzepatide pancreatitis risk looks like across different doses, that dedicated page draws on the published trial data.
If you are already on Mounjaro and want to talk through any symptoms or concerns ahead of your next review, our prescribers discuss suitability and side effects as part of every consultation. Start that conversation at our treatment page, or explore what Mounjaro involves if you are still deciding. Our clinical team is also available through aftercare, seven days a week.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.